A trispecific T-cell engager antibody has been developed that simultaneously binds to CD3, CD28, and CD38, both CD3 and CD28 engagement resulted in superior T cell activation, while the recognition of CD38 redirects T cells against MM and other hematologic malignancies with powerful killing efficiency [154]. This evidence concerns the gene CD38 and Miyoshi myopathy.